Ian Parish

Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com

Love the title: BACH2 the future!
www.nature.com/articles/s41...

We have an awesome organizing committee & stellar speaker line-up, all in a great location. This will be a small meeting with plenty of opportunities to meet with the speakers.

Register early so you don’t miss out as attendance will be capped.

www.aegeanconferences.org/src/App/conf...

Excited to announce the 1st International Conference on T cells in Health and Disease, a new conference series aiming to bring together T cell biologists across diverse areas, from fundamental biology through to clinical translation, and spanning infection, autoimmunity and cancer.

NOW ON YOUTUBE
youtu.be/5OHRntr_McU

'Understanding CD8+ T cell Tolerance'

Ian Parish, PhD
Assoc. Professor & Group Leader,
Peter MacCallum Cancer Centre
lnkd.in/gkXdZbRy
@IanParish_AU

🎙️@dmcmanus123

Thursday, Feb 19th, 2026
5pm ET | 4pm CT | 2pm PT
Zoom👇️
lnkd.in/gQime6rC

Huge congrats to @menezesnmaria.bsky.social for making this technically challenging project a reality. This was another fun collaboration with @paulbeavis4.bsky.social. Big thanks to all the members of the Beavis and Parish labs who contributed.

TCF1 is a master regulator of T cell stemness – but can it make exhausted cells go backwards?

We setup a CRISPR KI system to ask this question, and the answer was unexpected.

www.nature.com/articles/s41...

High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion @natcomms.nature.com @ianparish.bsky.social @petermaccc.bsky.social @paulbeavis4.bsky.social
www.nature.com/articles/s41...

OBS Immunology | Young Investigator Seminar

'Understanding CD8+ T cell Tolerance'

Ian Parish, PhD
Assoc. Professor & Group Leader,
Peter MacCallum Cancer Centre
tinyurl.com/Parish-Lab
@ianparish.bsky.social

🎙️@danmcmanus123.bsky.social

Thursday, Feb 19th, 2026
5pm ET | 4pm CT | 2pm PT
Zoom👇️

Atlas-guided discovery of transcription factors for T cell programming - Nature A comprehensive atlas platform integrating transcriptional and epigenetic data enables more precise engineering of T cell states, accelerating the rational design of more effective cellular immunother...

New study—and exciting collaboration with Wei Wang, Cong Liu (UCSD), and Kay Chung (new lab at UNC)—that provides a platform for designing T cells into specific states. We identified state-selective TFs for CD8 T cell states that enable “recipes” for cell engineering! www.nature.com/articles/s41...

A great piece in ACIR discussing the there papers on #BACH2 dosing for T cell therapy of cancer recently out in
@NatImmunol
bit.ly/3atHQyV

We have an active search for tenure-track faculty interested in #ImmuneEngineering #ProteinEngineering #GenomeEngineering & #CancerImmunology. Join the newly formed Center for Cellular Therapies and Cancer Immunology #CCTCI. Learn more at apply.interfolio.com/173562. #facultyjobs

Thanks Rahul, it was a pleasure to work with you, Alberto, Alex, Teresa and the rest of the team

Great to see this out, it was fun to work with Roychoudhuri lab on this really nice story. A good illustration that too much "stemness" in T cells can be a bad thing.

Peter Mac has been awarded $7.5M+ in @nhmrc.bsky.social Ideas Grant funding for five innovative projects tackling cancer metastasis, treatment resistance and immunotherapy.

An outstanding result in a highly competitive scheme!

Read more: www.petermac.org/about-us/new...

A $5 million @nhmrc grant will help Peter Mac researchers tackle one of cancer’s toughest challenges: advanced, metastatic disease.

The project, led by @belindaparker.bsky.social, will focus on understanding how metastatic cancers evade the immune system.

More: www.petermac.org/about-us/new...

👇See our newest study:
What was supposed to be a control experiment uncovered a new function of mTOR: 3’mediated translation control in primary human T cells, mediated through DDX21. AU-rich elements are required for this effect. Happy reading!
authors.elsevier.com/a/1mDFf3vVUP...

1/ We are making progress towards finding a cure for HIV. In a trial @UCSF led by Steve Deeks and @michaelpelusomd.bsky.social, 7/10 participants who received a combination of immunotherapies achieved partial control of HIV after stopping antiretroviral therapy (ART).🧵 www.nature.com/articles/s41...

We're hiring! We are looking for a Research Assistant with protein biochemistry skills to develop novel protein-based immunotherapeutics targeting Treg cells in cancer. You'll join
@roychoudhurilab.bsky.social @campathology.bsky.social @crukcamcentre.bsky.social Apply: jobs.cam.ac.uk/job/53219/

Distinct T cell functions enable efficient immunoediting and prevent tumor emergence of developing sarcomas Cheung et al. describe efficient T cell control of nascent neoantigen+ and nearby neoantigen-negative sarcoma cells, underlying a ∼50% reduction in tumor penetrance. This otherwise imperceptible immun...

Happy to announce the publication using advanced models to understand how T cells mediate efficient immunoediting in early sarcomas.

This was a collaboration between Julie Cheung and Brian Hunt
in the lab

Thanks to Cancer Cell for publishing our work.

www.cell.com/cancer-cell/...

Divergent cytokine and transcriptional signatures control functional T follicular helper cell heterogeneity - Nature Immunology Dalit, Tan and colleagues provide a multiomic profile of T follicular helper (TFH) cells responses to diverse pathogens, revealing a blueprint for transcriptional flexibility and new tools to interrog...

Thrilled to have our latest research @wehi-research.bsky.social published in @natimmunol.nature.com
www.nature.com/articles/s41...

This work was an outstanding partnership between talented PhD student Len Dalit (now postdoc, no 🦋) and bioinformatician @chinweetan.bsky.social

Thread below...

Divergent ontogeny of Tissue Resident Memory and Tissue Resident Exhausted CD8+ T cells underlies distinct functional potential Persistent antigen stimulation promotes differentiation of exhausted CD8+ T (TEX) cells. TEX cells are distinct from circulating memory T (TCIRCM) cells but share many features with tissue-resident me...

What's the difference between Trm and exhausted CD8 T cells? Simone Park's new work dissects this important question. These cell types are often confused, but are ontologically and mechanistically distinct with implications for immunotherapy responses. www.biorxiv.org/content/10.1...

The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells Understanding regulation of progenitor exhausted CD8+ T (Tpex) cell differentiation is important for immunotherapies. Humblin et al. report that sustained ICOS costimulation is detrimental to PD-1+CD8...

Link to the article below. Highly recommended reading!

www.cell.com/immunity/abs...

The high (I)COSt of costimulation for exhausted T cells ICOS agonists are being investigated for cancer immunotherapy based on the idea that they will reinvigorate exhausted CD8+ T cell anti-cancer immunity. Humblin et al. unexpectedly find the opposite—th...

It was a privilege and a pleasure for both myself and @menezesnmaria.bsky.social‬ to preview a great upcoming article in @cp-immunity.bsky.social‬ by @kamphorstlab.bsky.social‬ showing an unexpected inhibitory role for ICOS in exhausted CD8+ T cells.

www.cell.com/immunity/abs...

The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells Understanding regulation of progenitor exhausted CD8+ T (Tpex) cell differentiation is important for immunotherapies. Humblin et al. report that sustained ICOS costimulation is detrimental to PD-1+CD8+ T cell responses. Limiting ICOS signaling enhances Tpex cell stemness and differentiation into effector-like cells with improved survival and functionality. ICOSL blockade reinvigorates PD-1+CD8+ T cells and promotes viral or tumor control, potentiating PD-1 targeted immunotherapy.

Online now: The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1+CD8+ T cells

NR4A2 & RGS16 promoters support delivery of cytokines (e.g. IL-12) directly to the tumor site, leading to enhanced antitumor efficacy and long-term survival of mice in both syngeneic and xenogeneic models @nature.com @paulbeavis4.bsky.social
www.nature.com/articles/s41...

🎓 PhD positions available @MonashUni
Join our lab to explore how neurons and immune cells shape gut immunity!
🧬 Single-cell RNAseq
🔬 3D imaging
🧠 Neuro-immune interactions
👥 Great mentoring & collaborations

Apply now 👉 tinyurl.com/Seilletlab

We're looking for an experienced lab manager to join our wonderful team investigating fundamental T cell biology 🤓
careers.pageuppeople.com/513/cw/en/jo...

Join us as a group leader!!! Only a week left to apply to become part of our talented, fun and enthusiastic cancer research faculty in Melbourne.
👇

Group Leader - Melbourne (Suburb), Greater Melbourne (Inner) (AU) job with Peter MacCallum Cancer Centre | 12837590 Peter Mac is recruiting a Group Leader to increase the capacity and efficiency of our “discovery to translation” cancer research pipeline.

A group leader position is open at Peter Mac in Melbourne, Australia!
Join us! Applications until May 5.
👇👇

www.nature.com/naturecareer...

Thrilled to share new work led by @jieyang437.bsky.social in the lab published today in @Nature. We find that Aspirin prevents metastasis by releasing T cells from immune suppression by platelet TXA2. @Cambridge_Uni @CRUKCamCentre rdcu.be/eci1U